The early bird catches the discount! Register today for 50% off your 2026 registration with code EARLYBIRD at www.the3day.org/register. Hurry before this promotion flies away!

Let's make 2026 the year of healthy living! Taking care of yourself and having a sense of happiness and well-being is an important part of your health. What new things do you want to try this year?

Our “EmpowerED: Education After Diagnosis” event took place on Dec. 8, bringing together attendees for an evening of education, support and meaningful conversations, including a discussion about the power of asking for help and supporting one another. https://bit.ly/48KDOUk

Update! FDA approves T-DXd (trastuzumab deruxtecan) combined with petuzumab for HER2+ metastatic breast cancer as 1st line treatment - backed by DESTINY-Breast09 clinical trial results. Learn more here: https://bit.ly/4pIyc2V

"It's so important to always have advocates involved because it allows us to ask those questions to researchers like 'how will this help?'" - Komen patient advocate Bob Ritter shares his thoughts on all the research updates coming from @sabcs.bsky.social #SABCS

This week at #SABCS25, we presented pivotal work aimed at addressing needs within the #breastcancer community. Read more about the Komen-led research projects: https://bit.ly/4pyiJCe @sabcs.bsky.social#SABCS25

🔬 We’re watching the science at #SABCS25. Komen Scholar Susan Domchek, M.D., is excited about the WISDOM trial using genetics & polygenic risk scores to personalize screening. @sabcs.bsky.social#SABCS25 📖 Read more: https://www.komen.org/blog/sabcs-watch-2025/

🚀 At #SABCS25, Ben Park, MD, PhD showed how cell signals go "off the rails" in breast cancer and how his groundbreaking work with cfDNA is changing care by helping earlier detection, better treatment tracking, and spotting metastasis sooner. @sabcs.bsky.social

🎉 Congrats to Komen grantees Armando Giuliano MD and Nolan Priedigkeit MD for receiving awards at this year’s @sabcs.bsky.social! #SABCS25 👏👏

📢 We’re at #SABCS25! Stop by our booth in the Patient Advocacy Pavilion in the @sabcs.bsky.social#SABCS25Exhibition Hall! We’d love to talk to you about Komen’s mission including patient navigation, policy, research-support, education, and more!

Komen Scholar and Advocates in Science Steering Committee member Barbara Segarra-Vazquez highlights how advocates can drive meaningful change across research in the Partnership for Change session at #SABCS25. @sabcs.bsky.social

Komen grantee David Cescon discusses exciting advances in liquid biopsy tests for early breast cancer presented at #SABCS25. @sabcs.bsky.social

Komen Scholar Reshma Jagsi M.D., D. Phil. highlighted research at #SABCS25 that could reduce the burden of treatment, like fewer lymph node surgeries & radiation that boosts the immune system. 📖 See what’s ahead and what we’re excited to learn about @sabcs.bsky.social#SABCS25here: https://bit.ly/4pWBEqa

👏Komen honored our new early-career grantees during a celebration at #SABCS25. We are so proud to support the next generation of breast cancer leaders, investing in a talented workforce for years to come! 🎉 Learn more: https://bit.ly/49prhq1 @sabcs.bsky.social#SABCS25

Komen Scholar, Dr. Sunil Badve, presented how immune cells in residual tumors vary by breast cancer subtype in the ECOG-ACRIN EA1131 trial at #SABCS25. @sabcs.bsky.social

Another DESTINY-Breast09 update from Mothaffar Rimawi MD at #SABCS25: in HER2+ advanced breast cancer, first-line T-DXd + pertuzumab kept pain and daily functioning similar to standard THP, with more stomach issues but fewer skin and swelling symptoms 🩺📈 @sabcs.bsky.social

🩺🧬 Shanu Modi, MD shared DESTINY-Breast11 patient-reported outcomes: In high-risk HER2+ early breast cancer, T-DXd–based pre-surgery therapy helped more patients keep up physical functioning & daily activities vs ddAC-THP, with overall manageable side effects #SABCS25

At #SABCS25, Kevin Punie MD presented on ASCENT-03 patient-reported outcomes: In untreated advanced TNBC not eligible for immunotherapy, sacituzumab govitecan helped patients maintain physical activity and overall well-being better than chemo @sabcs.bsky.social

At #SABCS25, Jean Wright MD presented results from RadComp: In locally advanced breast cancer, proton radiation therapy gave lower average doses to the heart than photon RT. 💓 At 6 months, heart-related quality of life looked similar overall, with fatigue back to baseline @sabcs.bsky.social

At #SABCS25, Dr. Curigliano shared DESTINY-Breast11 data in high-risk HER2+ early breast cancer: T-DXd–based neoadjuvant regimens showed a more favorable safety profile, with fewer serious toxicities compared with ddAC-THP, while keeping side effects manageable 🩺🧬 @sabcs.bsky.social

💡 Komen Scholar Ben Park MD shares some hot topics at #SABCS25, including blood tests (liquid biopsies) that could transform how we detect and track #breastcancer. 📖 Read more about what we're watching @sabcs.bsky.social#SABCS25#breastcancerere: https://www.komen.org/blog/sabcs-watch-2025/

We’re tracking the biggest updates from #SABCS25, from liquid biopsies to genetics-guided screening🧬 #Breastcancer experts & MD’s: Ben Park, Reshma Jagsi & Susan Domchek shared what they’re watching & why it matters for patients in our blog: https://www.komen.org/blog/sabcs-watch-2025/ 💬

Breast cancer screening and early detection play an important role in your health. Screening tests can help find breast cancer at an early stage when the chances of survival are highest. Learn more about cancer screening: https://bit.ly/48RfhN7

The fight against breast cancer matters. That’s why we are committed to transparency and accountability in everything we do. Read our latest Impact Report to learn how your support is moving us closer to a world without breast cancer. https://bit.ly/3YKB0kE

Breast cancer is emerging as a global health crisis, yet with support from Komen, a groundbreaking tool called the Breast Cancer Care Quality Index is providing countries a roadmap to improve breast cancer care & save lives, regardless of the resources they have. Learn more: https://bit.ly/3X34dG8

Drumroll please! 🥁 We’re pleased to share the results of the 2026 Race for the Cure/MORE THAN PINK Walk T-shirt design poll. And the winner is… design #3! We can’t wait to see you rocking this new shirt in 2026!

🌍🔬 At ESMO 2025, breast cancer news went off: 📍Chemo-free options for HER2+ 📍Improved options in TNBC 📍Keeping cancer recurrence at bay 📍New options for metastatic ER+ BC Read the highlights in our blog: https://bit.ly/4hHohat

Many new treatments for MBC today are under study in clinical trials. Patient navigator Miranda Zinn shares how she and her team of navigators in the Komen Patient Care Center support the MBC community by guiding them to the right clinical trials. Learn more: https://bit.ly/4opdC72

🌍🔬 Day 3 #ESMO25 highlights: 📍Antibody drug conjugates transforming 1st-line treatment in metastatic breast cancer 📍Improved survival and longer disease control in HER2+ and TNBC @myesmo.bsky.social #breastcancer (1/4)

🌍🔬 Day 2 #ESMO25 highlights: 📍Potential new post-CDK4/6 options for ER+/HER2- metastatic BC 📍ADCs in early HER2+ breast cancer @myESMO #breastcancer (1/5)

🌍🔬Day 1 #ESMO25 highlights: 📍Pregnancy safety in HR+ breast cancer 📍New practice-confirming insight into adjuvant CDK4/6 inhibitors for early HR+/HER2- breast cancer @myESMO #breastcancer (1/4)

It’s #ESMO25 week 🎗️ We’re tracking new data and key breast cancer studies at the European Society for Medical Oncology. Follow us along here & on X for highlights and updates 💗 #BreastCancer #Oncology @myesmo.bsky.social#ESMO25

Today is National Donor Advised Fund Day! Consider using our quick and easy tool to make an immediate impact. Now more than ever, patients need your help. Ending breast cancer needs all of us. Komen.org/DAF #DAFDay

For someone with breast cancer, genomic testing can be a personalized guide that helps themchoose a treatment path with the greatest benefit while possibly avoiding unnecessary detours. Read more in the latest Know More blog: https://www.komen.org/blog/know-more-genomic-testing/

4 years ago, we released a first-of-its-kind report highlighting the breast cancer disparities bet. Black & white women. Today, we’re sharing an update: in 9 major U.S. metro areas where outcomes were the worst, more Black lives are being saved from breast cancer. Read more: https://bit.ly/4ojeKsz

October is National Breast Cancer Awareness Month and it's time to take action. From advocating for cancer research funding to supporting equitable care for all, your voice matters! Visit komen.org to join the fight. Because ending breast cancer needs all of us.

In case you missed it, check out the latest Breast Cancer Breakthroughs focused on how ctDNA is poised to revolutionize breast cancer care and read our blog to learn what it means for patients. Watch the event & read the blog here: https://bit.ly/48C56MO

Imlunestrant was just approved by the FDA to treat ER-positive, HER2-negative ESR1-mutated metastatic breast cancer. The approval was based on results from the phase 3 EMBER-3 clinical trial. Read more on our What's New Page: https://bit.ly/3IW3ToM

Breast cancer is rising in women under 50, but thanks to lifesaving clinical trials, there’s hope on the horizon. In our next Spotlight on Clinical Trials, we explore four current clinical trials that focus specifically on the needs of young women. https://bit.ly/42LaOrS

NEW Breast Cancer Breakthroughs Sept. 25! Learn about how simple blood tests are being used to improve breast cancer care. Info here: https://bit.ly/3X1yPW0

Discover how complementary therapies can support and empower breast cancer patients through treatment and recovery in our next Spotlight on Clinical Trials blog, where we explore three clinical trials testing their safety and effectiveness. Learn more: https://bit.ly/3KacV26

Komen is joining #RallyMedRes to call on Congress to protect lifesaving research! Research funded by the NIH is at the cornerstone of new advances for #breastcancer care. Take action and tell Congress to protect lifesaving research! #FundNIH #KomenAdvocacy

Nueva Vida is 1 of the 8 orgs in the ShareForCures alliance, and they are dedicated to supporting Latinos whose lives have been affected by cancer. Breast cancer affects people from all backgrounds, yet not every community is appropriately represented in research. Learn more: https://bit.ly/3K8umQA

Breast cancer is the leading cause of cancer death among Hispanic women in the U.S. We want to change that. This Hispanic Heritage Month, we encourage the Hispanic & Latino communities to take charge of their breast health, get screened & learn their family health histories. https://bit.ly/44Oxsy1

The stage of breast cancer when it is diagnosed is an important factor when determining prognosis. Learn about what each of these stages means: https://bit.ly/46iiNhb

We will never forget those we lost on Sept. 11, 2001.

Learn more about HER2+ MBC and the latest breakthroughs in research, clinical trials and treatment strategies at our upcoming MBC Impact Series. 🗓️ September 17th at 1pm CT / 2pm ET Register today: https://bit.ly/4m6PzaX Thank you to our partner AstraZeneca for supporting the MBC Impact Series.

Funding for #breastcancer early detection & research programs is moving forward in Congress. As Congress continues negotiations for the federal budget, we urge lawmakers to protect & invest in these lifelines. Read our statement: https://bit.ly/4m67Bdz

Susan G. Komen applauds today’s #SCOTUS decision to safeguard no-cost preventive care for more than 150 million Americans including #breastcancer patients, #survivors and those who are looking after their #breasthealth. Read more here: www.komen.org/news/susan-g...

Breast surgery is often a part of breast cancer treatment, but recovery can bring unexpected challenges. Get answers and tips in our Know More blog covering 4 surprising challenges and how to manage them. Read more: bit.ly/46eyc3y